ARCHIVES

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Rituxan Approved as Maintenance For Advanced Follicular Lymphoma

February 25, 2011

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

August 31, 1979

Troubled Roswell Park Cancer Institute Bets On Recruitment To Regain Its Luster.

January 19, 2001

Dispute At City of Hope Pits Center Against For-Profit Physician Group.

May 28, 2010

Letter to the Editors: AACR Defends Policy Paper And Work Of Barker, Sigal.

June 27, 2003

The Cancer Letter Wins Journalism Award

April 1, 2011